Poly ADP-ribose polymerase (PARP) inhibitors have played an increasing role in the treatment of ovarian cancer. They are being very heavily studied in clinical trials, both for the treatment of…
-150x100.jpg)
Susan Winn’s family history of ovarian and breast cancer can be traced back to the 1860s. Susan’s adult daughters, Kathryn, Bridget and Maureen, were recently interviewed with CURE® (Cancer Updates Research…
By Jack Gerard from In The Cloud Copy Medical response dogs are trained to recognize potential medical problems with their owners, alerting them or someone else when they detect a…
According to a story from Targeted Oncology, the US Food and Drug Administration (FDA) has granted Fast Track designation to the experimental drug OMP-305B83, also known as navicixiumab. This designation…
GlaxoSmithKline (GSK) has just announced that Zejula, otherwise known as niraparib, has just been approved for cancer patients beyond those who have a BRCA+ mutation. The patients now included in…
According to a publication from OncLive, the Food and Drug Administration (FDA) recently granted priority review status to a supplemental biologics license application for Zejula. Zejula (generic name niraparib) is…
According to a story from BioPortfolio, the biopharmaceutical company Clovis Oncology, Inc. recently released data from a phase 3 clinical trial of patients with recurrent ovarian cancer taking the company's…
According to a story from The Del Mar Times, the Susan Poorman Blackie Ovarian Cancer Foundation (SPB Foundation) and the Clearity Foundation have recently partnered in order to facilitate a…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
